Table of Contents Author Guidelines Submit a Manuscript
International Journal of Breast Cancer
Volume 2014 (2014), Article ID 769790, 7 pages
http://dx.doi.org/10.1155/2014/769790
Clinical Study

Efficacy and Safety of the All-Oral Schedule of Metronomic Vinorelbine and Capecitabine in Locally Advanced or Metastatic Breast Cancer Patients: The Phase I-II VICTOR-1 Study

1Oncology Department, AO S Gerardo, Via Pergolesi 33, 20900 Monza, Italy
2Istituto di Ricerche Farmacologiche “Mario Negri” Via La Masa, 19 20156 Milano, Italy

Received 12 August 2013; Revised 1 November 2013; Accepted 1 November 2013; Published 16 January 2014

Academic Editor: Zsuzsanna Kahán

Copyright © 2014 M. E. Cazzaniga et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. Sawada, K. Fujimoto-Ouchi et al., “Antitumour activity of combination therapy with CAPE plus VRB and CAPE plus gemcitabine in human tumour xenograft models,” American Association for Cancer Research, vol. 43, p. 1088, 2002. View at Google Scholar
  2. D. Hess, B. Thurlimann, O. Pagani et al., “CAPE and VRB as I line treatment in elderly patients with metastatic breast cancer,” Oncology, vol. 73, no. 3-4, pp. 228–237, 2008. View at Google Scholar · View at Scopus
  3. V. Lorusso, S. Cinieri, M. Giampaglia et al., “Intravenous versus oral vinorelbine plus capecitabine as second-line treatment in advanced breast cancer patients. A retrospective comparison of two consecutive phase II studies,” Breast, vol. 19, no. 3, pp. 214–218, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. F. Nolè, D. Crivellari, R. Mattioli et al., “Phase II study of an all-oral combination of vinorelbine with capecitabine in patients with metastatic breast cancer,” Cancer Chemotherapy and Pharmacology, vol. 64, no. 4, pp. 673–680, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. N. Tubiana-Mathieu, P. Bougnoux, D. Becquart et al., “All-oral combination of oral vinorelbine and capecitabine as first-line chemotherapy in HER2-negative metastatic breast cancer: an International Phase II Trial,” British Journal of Cancer, vol. 101, no. 2, pp. 232–237, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. R. S. Kerbel and B. A. Kamen, “The anti-angiogenic basis of metronomic chemotherapy,” Nature Reviews Cancer, vol. 4, no. 6, pp. 423–436, 2004. View at Google Scholar · View at Scopus
  7. S. Dellapasqua, F. Bertolini, V. Bagnardi et al., “Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer,” Journal of Clinical Oncology, vol. 26, no. 30, pp. 4899–4905, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. E. Briasoulis, P. Pappas, C. Puozzo et al., “Dose-ranging study of metronomic oral vinorelbine in patients with advanced refractory cancer,” Clinical Cancer Research, vol. 15, no. 20, pp. 6454–6461, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. Z. Saridaki, N. Malamos, P. Kourakos et al., “A Phase I trial or oral metronomic vinorelbine plus capecitabine in patients with metastatic breast cancer,” Cancer Chemotherapy and Pharmacology, vol. 69, no. 1, pp. 35–42, 2012. View at Publisher · View at Google Scholar
  10. V. Lorusso, M. Spada, M. Giampaglia et al., “Oral vinorelbine plus capecitabine (oral vincap) combination in patients with advanced breast cancer (ABC). A phase II study of the GOIM (Gruppo Oncologico dell'Italia Meridionale),” Annals of Oncology, vol. 17, supplement 7, pp. vii15–vii17, 2006. View at Publisher · View at Google Scholar · View at Scopus
  11. F. Nolè, C. Catania, G. Sanna et al., “Dose-finding and pharmacokinetic study of an all-oral combination regimen of oral vinorelbine and capecitabine for patients with metastatic breast cancer,” Annals of Oncology, vol. 17, no. 2, pp. 322–329, 2006. View at Publisher · View at Google Scholar · View at Scopus
  12. J. Finek, L. Holubec Jr., T. Svoboda et al., “A phase II trial of oral vinorelbine and capecitabine in anthracycline pretreated patients with metastatic breast cancer,” Anticancer Research, vol. 29, no. 2, pp. 667–670, 2009. View at Google Scholar · View at Scopus
  13. S. P. Gampenrieder, R. Bartsch, P. Matzneller et al., “Capecitabine and vinorelbine as an all-oral chemotherapy in HER2-negative locally advanced and metastatic breast cancer,” Breast Care, vol. 5, no. 3, pp. 158–162, 2010. View at Publisher · View at Google Scholar · View at Scopus
  14. A. Jones, M. O'Brien, H. Sommer et al., “Phase II study of oral vinorelbine in combination with capecitabine as second line chemotherapy in metastatic breast cancer patients previously treated with anthracyclines and taxanes,” Cancer Chemotherapy and Pharmacology, vol. 65, no. 4, pp. 755–763, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. B. T. Hennessy, A. M. Gauthier, L. B. Michaud, G. Hortobagyi, and V. Valero, “Lower dose capecitabine has a more favorable therapeutic index in metastatic breast cancer: retrospective analysis of patients treated at M. D. Anderson Cancer Center and a review of capecitabine toxicity in the literature,” Annals of Oncology, vol. 16, no. 8, pp. 1289–1296, 2005. View at Publisher · View at Google Scholar · View at Scopus